Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 403

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Open access
Gao, Chao, Cai, Yue, Zhang, Kan, Zhou, Lei, Zhang, Yao, Zhang, Xijing, Li, Qi, Li, Weiqin, Yang, Shiming, Zhao, Xiaoyan, Zhao, Yuying, Wang, Hui, Liu, Yi, Yin, Zhiyong, Zhang, Ruining, Wang, Rutao, Yang, Ming, Hui, Chen, Wijns, William, McEvoy, J William, Soliman, Osama, Onuma, Yoshinobu, Serruys, Patrick W, Tao, Ling, Li, Fei·2020·European Heart Journal

Abstract

Aims: It remains unknown whether the treatment of hypertension influences the mortality of patients diagnosed with coronavirus disease 2019 (COVID-19). Methods and results: This is a retrospective observational study of all patients admitted with COVID-19 to Huo Shen Shan Hospital. The hospital was dedicated solely to the treatment of COVID-19 in Wuhan, China. Hypertension and the treatments were stratified according to the medical history or medications administrated prior to the infection. Among 2877 hospitalized patients, 29.5% (850/2877) had a history of hypertension. After adjustment for confounders, patients with hypertension had a two-fold increase in the relative risk of mortality as compared with patients without hypertension [4.0% vs. 1.1%, adjusted hazard ratio (HR) 2.12, 95% confidence interval (CI) 1.17–3.82, P = 0.013]. Patients with a history of hypertension but without antihypertensive treatment (n = 140) were associated with a significantly higher risk of mortality compared with those with antihypertensive treatments (n = 730) (7.9% vs. 3.2%, adjusted HR 2.17, 95% CI 1.03–4.57, P = 0.041). The mortality rates were similar between the renin–angiotensin–aldosterone system (RAAS) inhibitor (4/183) and non-RAAS inhibitor (19/527) cohorts (2.2% vs. 3.6%, adjusted HR 0.85, 95% CI 0.28–2.58, P = 0.774). However, in a study-level meta-analysis of four studies, the result showed that patients with RAAS inhibitor use tend to have a lower risk of mortality (relative risk 0.65, 95% CI 0.45–0.94, P = 0.20). Conclusion: While hypertension and the discontinuation of antihypertensive treatment are suspected to be related to increased risk of mortality, in this retrospective observational analysis, we did not detect any harm of RAAS inhibitors in patients infected with COVID-19. However, the results should be considered as exploratory and interpreted cautiously.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa433

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 403

Metadata

Authors
Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., Li, Q., Li, W., Yang, S., Zhao, X., Zhao, Y., Wang, H., Liu, Y., Yin, Z., Zhang, R., Wang, R., Yang, M., Hui, C., Wijns, W., McEvoy, J. W., Soliman, O., Onuma, Y., Serruys, P. W., Tao, L., & Li, F.
Venue
European Heart Journal
Published
2020-06-04
Volume
41
Issue
22
Pages
2058-2066
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3032939692
Cited by
403
References
28
FWCI
10.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa433
The paper
Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., Li, Q., Li, W., Yang, S., Zhao, X., Zhao, Y., Wang, H., Liu, Y., Yin, Z., Zhang, R., Wang, R., Yang, M., Hui, C., Wijns, W., . . . Li, F. (2020). Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa433

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.